RxDoctor Payments Data

Misty Stambach, PA

Medical · Kansas City, MONPI 1396085395

Payments from drug & device makers

$844in general payments, 2019–2025

Across 11 payments — averaging $76.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$258
  • AstraZeneca$223
  • Tandem Diabetes Care, Inc.$143
  • Radius Health, Inc.$51
  • Amgen$50
  • Mannkind Corporation$43
  • plus $77 from 3 others

What the payments were for

  • Food & beverage$80295%
  • Education$435%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$844 in reported general payments places this provider in the 55th percentile of 198 medical providers in Missouri.

See all medical providers in Missouri

Medicare billing

Part B allowed, 2024
$31,491
Medicare patients
591
Services billed
1,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$104,989
JardianceEmpagliflozin70$86,093
TrulicityDulaglutide34$47,475
MounjaroTirzepatide14$27,064
FarxigaDapagliflozin Propanediol24$19,411
Tresiba Flextouch U-100Insulin Degludec33$16,154
EliquisApixaban15$14,864
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$6,364
Humalog Kwikpen U-100Insulin Lispro17$5,913
Insulin Lispro Kwikpen U-100Insulin Lispro12$2,675
Nano 2nd Gen Pen NeedlePen Needle, Diabetic20$1,824
Insulin Aspart FlexpenInsulin Aspart13$1,729
Gabapentin63$1,280
Albuterol Sulfate HfaAlbuterol Sulfate30$980
Rosuvastatin Calcium39$869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$223$19,41124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 198 medical providers in Missouri.

Other medical in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →